Associate, Asset Acquisition, GondolaBio

Job Description

Gondola Bio is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for genetic diseases. Originally launched as Bridge

BioX, a subsidiary of Bridge Bio, Gondola Bio secured $300M in private financing from external investors in 2024 and became an independent company within the Bridge Bio ecosystem. The company aims to leverage cutting‑edge biological research to create breakthrough medicines addressing high unmet needs across multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. Located on the Stanford Life Sciences campus, Gondola Bio fosters a unique hybrid environment where top scientists from around the world collaborate with senior leadership and advisors, blending industry expertise with academic innovation.

Bridge Bio is a commercial stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients.

Founded in 2015, the company built a portfolio of 22+ drug development programs ranging from preclinical to late‑stage development in multiple therapeutic areas including precision oncology, cardiology, endocrinology, neurology, pulmonology, renal disease, and genetic dermatology, with three approved drugs. We have U.S. offices in San Francisco, Palo Alto, and Raleigh. We also have international offices in Montreal, Canada, and Switzerland.

Gondola Bio’s Asset Acquisition team is seeking an Associate to help us define our new programs. We are looking for ambitious scientists who’d like to contribute at the intersection of science and business. Our team is responsible for finding, evaluating, and determining which therapeutic ideas Gondola Bio will pursue, with an emphasis on evaluation of the scientific rationale behind therapeutic strategies.

The team works closely with Gondola Bio’s Investment Committee, which is composed of veteran drug developers and renowned academic scientists. Across the Bridge Bio ecosystem, we have spearheaded partnerships with academic and industry groups to create, fund, and operate >

30 new drug development programs. As a key member of the team, this position will help set the culture and business development of the company and will be the face of the organization.

• Identify promising new preclinical or early clinical stage programs to treat genetically driven diseases through deep engagement with the literature, academic and industry experts, and internal development efforts
• Deeply evaluate all aspects of a potential therapeutic program—from genetic rationale and pre‑clinical evidence all the way to the development plan and clinical trial design
• Advocate for those that fit our goal of targeting the genetic source of a disease by building a scientific and business case for each potential investment
• Interface with leading academics, patient advocacy groups, biotechs, and entrepreneurs
• Lead internal discussions with management and the Investment Committee
• Establish a focused investment strategy and follow through to identify new investment opportunities
• Coordinate and work with a talented team of internal subject‑matter experts—including clinical, commercial, and disease experts—to dive as deeply as needed for each project

• You are patient driven - Everything we do impacts the life of a Patient
• You have a strong aptitude and detailed curiosity for science (you devour journals for breakfast)
• You hold an advanced technical degree (PhD, MD, or MD+PhD) in the life sciences and / or medicine, from a top‑tier academic institution.
• Postdoctoral or residency training is a strong plus.
• You have a demonstrated record of scientific achievement as evidenced by…